Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B antibodies
- Development stage
- Phase 1
- Lead developer
- Region Midtjylland
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Hepatitis B antibodies, in the context of the SAMBA clinical trial, refers to an investigational combination of two human monoclonal antibodies (mAbs), designated as HBV-1 and HBV-2. Developed by researchers at Aarhus University and Aarhus University Hospital and sponsored by Region Midtjylland, these antibodies are designed to target the Hepatitis B surface antigen (HBsAg). The mechanism involves binding to and neutralizing HBsAg, which is intended to clear viral particles from the circulation and potentially overcome the immune tolerance characteristic of chronic hepatitis B infection. This therapeutic approach aims to achieve a "functional cure" by restoring the patient's own immune response against the virus. The combination is currently being evaluated in a Phase 1 ascending dose study (SAMBA) to assess its safety, tolerability, and preliminary antiviral effects in individuals with chronic hepatitis B.
- Other names
- SAMBA antibodiesAarhus HBV antibodiesHBV-1 + HBV-2
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B antibodies.